Prior immunotherapy enhances survival outcomes of third‐line apatinib treatment in advanced gastric cancer: A retrospective cohort study
Authors:
- 29 December 2025
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 158 (11) , 2912-2919
Abstract
The impact of prior immune checkpoint inhibitor (ICI) therapy on subsequent antiangiogenic treatment efficacy in advanced gastric cancer remains unclear. We retrospectively analyzed 134 patients with advanced gastric cancer who received apatinib as third‐line treatment between January 2018 and October 2023, comparing outcomes between those with ( n = 66) and without ( n = 68) prior ICI exposure. The ICI‐pretreated group demonstrated significantly improved survival outcomes, with longer median progression‐free survival (7.1 vs. 4.2 months; HR = 0.42, 95% CI: 0.24–0.75, p = .003) and overall survival (9.0 vs. 5.1 months; HR = 0.53, 95% CI: 0.31–0.91, p = .023) compared to the ICI‐naive group. Disease control rate was also higher in ICI‐pretreated patients (72.7% vs. 61.8%). Subgroup analyses revealed particularly pronounced survival benefits among male patients (HR = 0.30, 95% CI: 0.14–0.65), HER2‐negative patients (HR = 0.35, 95% CI: 0.18–0.69), and those with liver metastases (HR = 0.33, 95% CI: 0.15–0.76, p = .009). Prior ICI therapy emerged as an independent favorable prognostic factor for survival in multivariate analysis. These findings suggest that prior ICI therapy may enhance the efficacy of subsequent third‐line apatinib treatment in patients with advanced gastric cancer, providing important insights for optimizing treatment sequencing strategies in this setting.Keywords
This publication has 21 references indexed in Scilit:
- Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategiesCell Death & Disease, 2025
- Role of T cells in liver metastasisCell Death & Disease, 2024
- Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapyInternational Journal of Cancer, 2024
- VEGF signaling: Role in angiogenesis and beyondBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024
- Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction CancerJAMA, 2023
- The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling studyeClinicalMedicine, 2022
- Advances in clinical immunotherapy for gastric cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Outcomes on anti‐VEGFR‐2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinomaInternational Journal of Cancer, 2021
- Treatment Strategies of Gastric Cancer—Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art ReviewJournal of Gastrointestinal Cancer, 2021
- A human receptor occupancy assay to measure anti‐PD‐1 binding in patients with prior anti‐PD‐1Cytometry Part A, 2021